Literature DB >> 35779123

Impact of converging sociocultural and substance-related trends on US autism rates: combined geospatiotemporal and causal inferential analysis.

Albert Stuart Reece1,2, Gary Kenneth Hulse3,4.   

Abstract

Whilst cannabis is known to be toxic to brain development, it is unknown if it is driving rising US autism rates (ASMR). A longitudinal epidemiological study was conducted using national autism census data from the US Department of Education Individuals with Disabilities Act (IDEA) 1991-2011 and nationally representative drug exposure (cigarettes, alcohol, analgesic, and cocaine abuse, and cannabis use monthly, daily, and in pregnancy) datasets from National Survey of Drug Use and Health and US Census (income and ethnicity) and CDC Wonder population and birth data. Analysis was conducted in R. 266,950 were autistic of a population of 40,119,464 8-year-olds in 1994-2011. At national level after adjustment, daily cannabis use was significantly related to ASMR (β estimate = 4.37 (95%C.I. 4.06, 4.68), P < 2.2 × 10-16) as was first pregnancy trimester cannabis exposure (β estimate = 0.12 (0.08, 0.16), P = 1.7 × 10-12). At state level following adjustment for cannabis, cannabigerol (from β estimate = - 13.77 (- 19.41, 8.13), P = 1.8 × 10-6) and Δ9-tetrahydrocannabinol (from β estimate = 1.96 (0.88-3.04), P = 4 × 10-4) were significant. Geospatial state-level modelling showed exponential relationship between ASMR and Δ9-tetrahydrocannabinol and cannabigerol exposure. Exponential coefficients for the relationship between modelled ASMR and Δ9-tetrahydrocannabinol and cannabigerol exposure were 7.053 (6.39-7.71) and 185.334 (167.88-202.79; both P < 2.0 × 10-7). E-values are an instrument related to the evidence for causality in observational studies. High E-values were noted. Dichotomized legal status was linked with elevated ASMR. Data show cannabis use is associated with ASMR, is powerful enough to affect overall trends, and persists after controlling for other major covariates. Cannabinoids are exponentially associated with ASMR. The cannabis-autism relationship satisfies criteria of causal inference.
© 2022. The Author(s).

Entities:  

Keywords:  Cannabigerol; Cannabinoid; Cannabis; Pathways and mechanisms; Δ9-tetrahydrocannabinol

Year:  2022        PMID: 35779123     DOI: 10.1007/s00406-022-01446-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  42 in total

1.  Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States.

Authors:  Mahmoud A ElSohly; Zlatko Mehmedic; Susan Foster; Chandrani Gon; Suman Chandra; James C Church
Journal:  Biol Psychiatry       Date:  2016-01-19       Impact factor: 13.382

Review 2.  Advanced parental age and autism risk in children: a systematic review and meta-analysis.

Authors:  S Wu; F Wu; Y Ding; J Hou; J Bi; Z Zhang
Journal:  Acta Psychiatr Scand       Date:  2016-11-14       Impact factor: 6.392

3.  Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997.

Authors:  M A ElSohly; S A Ross; Z Mehmedic; R Arafat; B Yi; B F Banahan
Journal:  J Forensic Sci       Date:  2000-01       Impact factor: 1.832

4.  Inflammation and Autism: From Maternal Gut to Fetal Brain.

Authors:  Ivan Osokine; Adrian Erlebacher
Journal:  Trends Mol Med       Date:  2017-11-06       Impact factor: 11.951

5.  Maternal cannabis use in pregnancy and child neurodevelopmental outcomes.

Authors:  Daniel J Corsi; Jessy Donelle; Ewa Sucha; Steven Hawken; Helen Hsu; Darine El-Chaâr; Lise Bisnaire; Deshayne Fell; Shi Wu Wen; Mark Walker
Journal:  Nat Med       Date:  2020-08-10       Impact factor: 53.440

6.  Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014.

Authors:  Jon Baio; Lisa Wiggins; Deborah L Christensen; Matthew J Maenner; Julie Daniels; Zachary Warren; Margaret Kurzius-Spencer; Walter Zahorodny; Cordelia Robinson Rosenberg; Tiffany White; Maureen S Durkin; Pamela Imm; Loizos Nikolaou; Marshalyn Yeargin-Allsopp; Li-Ching Lee; Rebecca Harrington; Maya Lopez; Robert T Fitzgerald; Amy Hewitt; Sydney Pettygrove; John N Constantino; Alison Vehorn; Josephine Shenouda; Jennifer Hall-Lande; Kim Van Naarden Braun; Nicole F Dowling
Journal:  MMWR Surveill Summ       Date:  2018-04-27

7.  California Autism Prevalence Trends from 1931 to 2014 and Comparison to National ASD Data from IDEA and ADDM.

Authors:  Cynthia Nevison; Mark Blaxill; Walter Zahorodny
Journal:  J Autism Dev Disord       Date:  2018-12

8.  Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling.

Authors:  Csaba Földy; Robert C Malenka; Thomas C Südhof
Journal:  Neuron       Date:  2013-04-11       Impact factor: 17.173

9.  Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.

Authors:  Kwang-Mook Jung; Marja Sepers; Christopher M Henstridge; Olivier Lassalle; Daniela Neuhofer; Henry Martin; Melanie Ginger; Andreas Frick; Nicholas V DiPatrizio; Ken Mackie; Istvan Katona; Daniele Piomelli; Olivier J Manzoni
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

10.  Advanced parental age and the risk of autism spectrum disorder.

Authors:  Maureen S Durkin; Matthew J Maenner; Craig J Newschaffer; Li-Ching Lee; Christopher M Cunniff; Julie L Daniels; Russell S Kirby; Lewis Leavitt; Lisa Miller; Walter Zahorodny; Laura A Schieve
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.